Successful reduction of NAPPA score (Nail Assessment in Psoriasis and Psoriasis-Arthritis) under secukinumab in severe nail psoriasis
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
Dermatologie (Heidelberg, Germany) - 75(2024), 2 vom: 10. Feb., Seite 149-152 |
| Sprache: |
Deutsch |
|---|
| Weiterer Titel: |
Erfolgreiche Reduzierung der NAPPA-Scores (Nail Assessment in Psoriasis and Psoriasis-Arthritis) mit Secukinumab bei schwerer Nagelpsoriasis |
|---|
| Beteiligte Personen: |
Alhumam, Aminah [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 30.01.2024 Date Revised 01.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00105-023-05235-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363169563 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363169563 | ||
| 003 | DE-627 | ||
| 005 | 20240201231948.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||ger c | ||
| 024 | 7 | |a 10.1007/s00105-023-05235-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1277.xml |
| 035 | |a (DE-627)NLM363169563 | ||
| 035 | |a (NLM)37823915 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a ger | ||
| 100 | 1 | |a Alhumam, Aminah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Successful reduction of NAPPA score (Nail Assessment in Psoriasis and Psoriasis-Arthritis) under secukinumab in severe nail psoriasis |
| 246 | 3 | 3 | |a Erfolgreiche Reduzierung der NAPPA-Scores (Nail Assessment in Psoriasis and Psoriasis-Arthritis) mit Secukinumab bei schwerer Nagelpsoriasis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.01.2024 | ||
| 500 | |a Date Revised 01.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a secukinumab |2 NLM | |
| 650 | 7 | |a DLG4EML025 |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t Dermatologie (Heidelberg, Germany) |d 2022 |g 75(2024), 2 vom: 10. Feb., Seite 149-152 |w (DE-627)NLM330027379 |x 2731-7013 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2024 |g number:2 |g day:10 |g month:02 |g pages:149-152 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00105-023-05235-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2024 |e 2 |b 10 |c 02 |h 149-152 | ||